CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Biogen Inc. (NASDAQ: BIIB) announced today that Bioverativ, the planned spin-off of Biogen’s hemophilia business, will host an Investor Day on January 6, 2017. The webcast will be live on Friday, January 6, 2017 at 10:00a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation.
The planned spin-off of Bioverativ is expected to be completed on February 1, 2017.
Following the spin-off, Bioverativ will be an independent, publicly-held global biotechnology company dedicated to advancing the research, development and commercialization of innovative therapies to address areas of serious unmet need for people with hemophilia and other rare blood disorders.
About Biogen
Through cutting-edge science and medicine,
Biogen discovers, develops and delivers worldwide innovative therapies
for people living with serious neurological, autoimmune and rare
diseases. Founded in 1978, Biogen is one of the world’s oldest
independent biotechnology companies and patients worldwide benefit from
its leading multiple sclerosis and innovative hemophilia therapies. For
more information, please visit www.biogen.com.
Follow us on Twitter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161222005043/en/
